358 related articles for article (PubMed ID: 28322294)
21. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
Min SH; Yoon JH; Hahn S; Cho YM
Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
[TBL] [Abstract][Full Text] [Related]
22. Acarbose With Comparable Glucose-Lowering but Superior Weight-Loss Efficacy to Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Zhang F; Xu S; Tang L; Pan X; Tong N
Front Endocrinol (Lausanne); 2020; 11():288. PubMed ID: 32582019
[No Abstract] [Full Text] [Related]
23. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with moderate to severe renal impairment: a systematic review and meta-analysis.
Cheng D; Fei Y; Liu Y; Li J; Chen Y; Wang X; Wang N
PLoS One; 2014; 9(10):e111543. PubMed ID: 25360775
[TBL] [Abstract][Full Text] [Related]
24. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
25. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies.
Li L; Li S; Deng K; Liu J; Vandvik PO; Zhao P; Zhang L; Shen J; Bala MM; Sohani ZN; Wong E; Busse JW; Ebrahim S; Malaga G; Rios LP; Wang Y; Chen Q; Guyatt GH; Sun X
BMJ; 2016 Feb; 352():i610. PubMed ID: 26888822
[TBL] [Abstract][Full Text] [Related]
26. Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes.
Liu X; Liu Y; Liu H; Li H; Yang J; Hu P; Xiao X; Liu D
Front Endocrinol (Lausanne); 2021; 12():694390. PubMed ID: 34616361
[TBL] [Abstract][Full Text] [Related]
27. Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism.
Ahrén B; Foley JE
Diabetologia; 2016 May; 59(5):907-17. PubMed ID: 26894277
[TBL] [Abstract][Full Text] [Related]
28. A meta-analysis of the effect of angiotensin receptor blockers and calcium channel blockers on blood pressure, glycemia and the HOMA-IR index in non-diabetic patients.
Yang Y; Wei RB; Xing Y; Tang L; Zheng XY; Wang ZC; Gao YW; Li MX; Chen XM
Metabolism; 2013 Dec; 62(12):1858-66. PubMed ID: 24050270
[TBL] [Abstract][Full Text] [Related]
29. The efficacy and safety of dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus patients with severe renal impairment: a meta-analysis.
Chen M; Liu Y; Jin J; He Q
Ren Fail; 2016; 38(4):581-7. PubMed ID: 26915531
[TBL] [Abstract][Full Text] [Related]
30. Dipeptidyl peptidase-4 inhibitors and risk of arthralgia: A systematic review and meta-analysis.
Men P; He N; Song C; Zhai S
Diabetes Metab; 2017 Dec; 43(6):493-500. PubMed ID: 28778563
[TBL] [Abstract][Full Text] [Related]
31. Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-Naïve Patients with Type 2 Diabetes.
Ito R; Fukui T; Hayashi T; Osamura A; Ohara M; Hara N; Higuchi A; Yamamoto T; Hirano T
Drugs R D; 2015 Sep; 15(3):245-51. PubMed ID: 26224337
[TBL] [Abstract][Full Text] [Related]
32. Dipeptidyl peptidase-4 inhibitor sitagliptin improves pancreatic β-cell function in hypertensive diabetic patients treated with angiotensin receptor blockers.
Fukui K; Kawahito H; Wakana N; Kikai M; Terada K; Yamamoto K; Irie D; Kato T; Miyagawa S; Yamada H
J Renin Angiotensin Aldosterone Syst; 2015 Dec; 16(4):1001-9. PubMed ID: 26195265
[TBL] [Abstract][Full Text] [Related]
33. Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study.
Zhao Y; Yang L; Xiang Y; Liu L; Huang G; Long Z; Li X; Leslie RD; Wang X; Zhou Z
J Clin Endocrinol Metab; 2014 May; 99(5):E876-80. PubMed ID: 24432999
[TBL] [Abstract][Full Text] [Related]
34. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis.
Salvo F; Moore N; Arnaud M; Robinson P; Raschi E; De Ponti F; Bégaud B; Pariente A
BMJ; 2016 May; 353():i2231. PubMed ID: 27142267
[TBL] [Abstract][Full Text] [Related]
35. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis.
Kim YG; Hahn S; Oh TJ; Kwak SH; Park KS; Cho YM
Diabetologia; 2013 Apr; 56(4):696-708. PubMed ID: 23344728
[TBL] [Abstract][Full Text] [Related]
36. Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes.
Geng J; Yu H; Mao Y; Zhang P; Chen Y
Pharmacoeconomics; 2015 Jun; 33(6):581-97. PubMed ID: 25736235
[TBL] [Abstract][Full Text] [Related]
37. Effect of Dipeptidyl Peptidase-4 Inhibitors on Plasma Adiponectin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Sahebkar A; Ponzo V; Bo S
Curr Med Chem; 2016; 23(13):1356-69. PubMed ID: 27048342
[TBL] [Abstract][Full Text] [Related]
38. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
Ahrén B; Pacini G; Tura A; Foley JE; Schweizer A
Horm Metab Res; 2007 Nov; 39(11):826-9. PubMed ID: 17992639
[TBL] [Abstract][Full Text] [Related]
39. Alogliptin benzoate for management of type 2 diabetes.
Saisho Y
Vasc Health Risk Manag; 2015; 11():229-43. PubMed ID: 25914541
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review.
Frandsen CS; Madsbad S
Diabet Med; 2014 Nov; 31(11):1293-300. PubMed ID: 25112609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
